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OBJECTIVE — Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are
considered pre-diabetes states. There are limited data in pediatrics in regard to their pathophys-
iology. We investigated differences in insulin sensitivity and secretion among youth with IFG,
IGT, and coexistent IFG/IGT compared with those with normal glucose tolerance (NGT) and
type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Atotalof24obeseadolescentswithNGT,13
with IFG, 29 with IGT, 11 with combined IFG/IGT, and 30 with type 2 diabetes underwent
evaluation of hepatic glucose production ([6,6-
2H2]glucose), insulin-stimulated glucose dis-
posal (Rd, euglycemic clamp), ﬁrst- and second-phase insulin secretion (hyperglycemic clamp),
body composition (dual-energy X-ray absorptiometry), abdominal adiposity (computed tomog-
raphy), and substrate oxidation (indirect calorimetry).
RESULTS — Adolescents with NGT, pre-diabetes, and type 2 diabetes had similar body
composition and abdominal fat distribution. Rd was lower (P  0.009) in adolescents with type
2 diabetes than in those with NGT. Compared with adolescents with NGT, ﬁrst-phase insulin
was lower in those with IFG, IGT, and IFG/IGT with further deterioration in those with type 2
diabetes(P0.001),and-cellfunctionrelativetoinsulinsensitivity(glucosedispositionindex
[GDI])wasalsolowerinthosewithIFG,IGT,andIFG/IGT(40,47,and47%,respectively),with
a further decrease (80%) in those with type 2 diabetes (P  0.001). GDI was the major deter-
minant of fasting and 2-h glucose levels.
CONCLUSIONS — Obese adolescents who show signs of glucose dysregulation, including
abnormal fasting glucose, glucose intolerance or both, are more likely to have impaired insulin
secretionratherthanreducedinsulinsensitivity.Giventheimpairmentininsulinsecretion,they
are at high risk for progression to type 2 diabetes. Further deterioration in insulin sensitivity or
secretion may enhance the risk for this progression.
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re-diabetes, deﬁned as the presence
of elevated fasting glucose, abnor-
malglucosetolerance,orboth,isas-
sociated with an enhanced risk for
development of type 2 diabetes in adults
(1),buttherearelimiteddatatodeﬁnethe
signiﬁcance in children. A recent change
in the deﬁnition of the abnormal fasting
glucose to a lower level (100–125 mg/dl)
has increased the prevalence of pre-
diabetes in both adults and youth (2–4).
Itisunclearfromtheliteraturewhatrolea
defect in insulin secretion or an abnor-
mality of insulin sensitivity might play in
the impairment of glucose regulation,
leading to glucose intolerance or elevated
fasting plasma glucose.
Epidemiological studies suggest that
subjects with impaired fasting glucose
(IFG) have lower insulin sensitivity and
higher insulin secretion (5,6) based
largely on fasting indexes of insulin sen-
sitivity and an oral glucose tolerance
(OGTT)–derived single index of insulin
secretion (5). Adult studies reveal similar
or lower insulin sensitivity in subjects
with impaired glucose tolerance (IGT)
compared with those with IFG who have
lower insulin secretion (7,8). These stud-
ies are contrasted with clamp studies in
PimaIndiansshowingsimilarinsulinsen-
sitivity in subjects with IFG and IGT but
lower insulin secretion in those with fast-
ing dysglycemia (9).
Pediatric data are limited. In over-
weight Latino children with a family his-
tory of type 2 diabetes (10), children with
impaired versus normal fasting glucose
had no signiﬁcant differences in insulin
sensitivity or acute insulin response.
However, the glucose disposition index
(GDI), or insulin secretion relative to in-
sulin sensitivity, was signiﬁcantly re-
duced (15% lower) in children with IFG.
A more recent study in obese adolescents
revealed that subjects with IFG had de-
creased glucose sensitivity of ﬁrst-phase
insulin secretion and liver insulin sensi-
tivity, whereas those with IGT had more
severe degrees of peripheral insulin resis-
tance compared with subjects with nor-
mal glucose tolerance (NGT) (11). We
recently demonstrated that insulin secre-
tion relative to insulin sensitivity shows a
signiﬁcantly declining pattern: highest in
youth with NGT, intermediate in youth
withIGT,andlowestinyouthwithtype2
diabetes (12).
In an attempt to clarify the contro-
versy concerning the metabolic derange-
ments in the different categories of the
pre-diabetes state, the aims of the present
study were to 1) to investigate the meta-
bolic characteristics of insulin sensitivity
and secretion in obese youth, with IFG
versus IGT, of similar body composition
and abdominal adiposity and 2) to com-
pare them not only with those with NGT
but also with children with type 2
diabetes.
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METHODS— Twenty-four obese
adolescents with NGT, 13 with IFG, 29
with IGT, 11 with combined IFG/IGT,
and 30 with type 2 diabetes (African
American n  45 and American white
n  62) adolescents were studied. IFG
was deﬁned according to the 2003
American Diabetes Association (ADA)
guidelines as fasting plasma glucose
(FPG) of 100–125 mg/dl (13), based
on the average of two fasting glucose
measurements at the time of the OGTT
(at 15 and 0 min) or the average of
seven fasting glucose measurements ob-
tainedduringthetwoclampprocedures
(threesamplesevery15minatthebase-
line of the hyperglycemic clamp and
four samples every 10 min at the base-
line of the euglycemic clamp) and NGT
with 2-h post-OGTT glucose of 140
mg/dl. IGT was deﬁned as normal FPG
100 mg/dl and 2-h post-OGTT glu-
cose of 140–199 mg/dl according to
ADAcriteria(13).Thosewithcombined
IFG/IGT had FPG 100–125 mg/dl
and2-hglucosebetween140and199
mg/dl (13). All subjects were pubertal
and had exogenous obesity with no
clinical evidence of endocrinopathy as-
sociated with obesity. They were not in-
volved in any regular physical activity
or weight reduction programs. Type 2
diabetes in the adolescents was clini-
cally diagnosed according to ADA and
World Health Organization criteria
(14). Type 2 diabetic adolescents were
negative for GAD and insulinoma-
associated protein-2 autoantibody.
They were being treated with lifestyle
alone(n  7),metformin(n  11),met-
formin  insulin (n  10), or insulin
alone (n  2). All other participants
were not taking any medications that
affect glucose metabolism. In type 2 di-
abetic subjects, metformin and long-
acting insulin were discontinued 48 h
before the clamp studies. Some of the
participants (12 with NGT, 19 with
IGT, and 17 with type 2 diabetes) have
been reported before (12). All studies
were approved by the institutional re-
view board of the University of Pitts-
burgh. Informed consent was obtained.
Clinicalcharacteristicsofthestudysub-
jects are summarized in Table 1.
Clamp studies
Participants were admitted twice within a
1- to 3-week period to the Pediatric Clin-
ical and Translational Research Center on
the day before the clamp studies, once for
a hyperinsulinemic-euglycemic clamp
and the other time for a hyperglycemic
clamp in random order. The 2-h OGTT
(1.75 g/kg Glucola [maximum 75 g]) was
performed on the day before the ﬁrst Pe-
diatric Clinical and Translational Re-
search Center admission.
In vivo insulin-stimulated glucose
disposal
A fasting blood sample was obtained for
determination of cholesterol, LDL, HDL,
VLDL,triglycerides,A1C,proinsulin,and
C-peptide. Fasting endogenous glucose
production was measured with a primed
constant rate infusion of [6,6-
2H2] glu-
cose (0.306  0.009 mol/kg/min; Iso-
tech, Miamisburg, OH) (12). Insulin-
mediated glucose metabolism (Rd) and
insulinsensitivitywereevaluatedduringa
3-h hyperinsulinemic-euglycemic clamp
(12). Continuous indirect calorimetry by
a ventilated hood (Deltatrac Metabolic
Monitor, Sensormedics, Anaheim, CA)
was used to measure CO2 production, O2
consumption, and respiratory quotient.
Measurements were made for 30 min at
baseline and at the end of the euglycemic
clamp (12).
In vivo insulin secretion
First- and second-phase insulin and C-
peptidesecretionwereevaluatedduringa
2-h hyperglycemic clamp (12.5 mmol/l)
as before (12).
Body composition
Bodycompositionwasdeterminedbydu-
al-energy X-ray absorptiometry and sub-
cutaneous abdominal adipose tissue and
visceral adipose tissue by a single-slice
computed tomography scan at L4–L5
(12).
Biochemical measurements
Plasma glucose was measured with a glu-
cose analyzer (YSI, Yellow Springs, OH);
insulin and C-peptide were measured by
radioimmunoassay as before (12). A1C
was measured by high-performance liq-
uidchromatography(TosohMedics),and
lipids were measured using the standards
of the Centers for Disease Control and
Prevention (12). Deuterium enrichment
of glucose in the plasma was determined
on a Hewlett-Packard (Palo Alto, CA)
5973 mass spectrometer coupled to a
6890 gas chromatograph (12). Pancreatic
autoantibodies were determined in the
Northwest Lipid Metabolism and Diabe-
tes Research Laboratories, University of
Washington (Seattle, WA) using the Na-
tional Institute of Diabetes and Digestive
and Kidney Diseases–sponsored stan-
dardization assay.
Calculations
Fasting hepatic glucose production
(HGP) was calculated during the last 30
min of the 2-h isotope infusion accord-
ing to steady-state tracer dilution equa-
tions (12). In the fasting state, an index
of hepatic insulin resistance was calcu-
lated as the product of HGP and fasting
insulin levels (14). Insulin-stimulated
glucose disposal rate (Rd) was calcu-
lated during the last 30 min of the eu-
glycemicclamptobeequaltotherateof
exogenous glucose infusion and ex-
pressed per fat free mass (FFM) (milli-
grams per minute per kilogram FFM).
Peripheral insulin sensitivity was calcu-
lated by dividing the Rd by the steady-
state clamp insulin level and expressed
per FFM (milligrams per minute per
FFM per microunits per milliliter) (12).
Insulin-stimulated carbohydrate oxida-
tion rates were calculated according to
the formulas of Frayn (12).
During the hyperglycemic clamp, the
ﬁrst- and second-phase insulin and C-
peptideconcentrationswerecalculatedas
described previously (12). The GDI was
calculated as the product of insulin sensi-
tivity  ﬁrst-phase insulin and expressed
as milligrams per minute per kilogram
FFM.
Statistics
Statistical analyses were performed using
ANOVA followed by a post hoc Bonfer-
roni correction for ﬁve group compari-
sons. A Kruskal-Wallis test was used for
multiple group comparison of nonpara-
metric variables and a 	
2 test to evaluate
categorical variables. Spearman’s correla-
tion and multiple regression analyses
wereusedtoevaluatebivariateandmul-
tivariate relationships, respectively.
Nonparametric variables were log-
transformed for the regression analyses.
Data are presented as means  SD. Two-
tailed P  0.05 was considered statisti-
cally signiﬁcant.
RESULTS
Study subjects and fasting metabolic
proﬁle
Table 1 depicts characteristics of the ﬁve
groups of obese adolescents with NGT,
IFG, IGT, combined IFG/IGT, and type 2
diabetes. There were no signiﬁcant differ-
ences in age, sex, Tanner stage, or ethnic
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subjectswerepubertal.Therewerenosig-
niﬁcant differences in BMI, percent body
fat, or abdominal visceral or subcutane-
ous fat among the ﬁve groups.
Fastingglucosewasdifferentamong
the groups as expected on the basis of
predeﬁnedcategorization.Therewasno
difference in fasting insulin levels
among the ﬁve groups. Fasting endoge-
nous glucose production (HGP) was
signiﬁcantly higher in the type 2 dia-
betic group compared with the NGT
group (post hoc P  0.004) with no
difference among the pre-diabetic
groups. Postabsorptive hepatic insulin
resistance tended to be higher in the
type 2 diabetic group versus the NGT
group (post hoc P  0.07) with no dif-
ference among the other pre-diabetic
groups. The proinsulin-to-insulin ratio
was higher in the type 2 diabetic group
but not signiﬁcantly higher in the pre-
diabetic groups compared with the
NGT group. The fasting lipid proﬁle
was not different among the groups
(Table 1).
In vivo insulin-stimulated glucose
disposal and insulin secretion
Total, oxidative, and nonoxidative glu-
cose disposal were lower in the type 2
diabetic group compared with the NGT
group. Oxidative glucose disposal was
lower in the type 2 diabetic group com-
pared with the NGT (P  0.016), IFG
(P  0.003), and IGT (P  0.023) groups
in post hoc analysis but was not different
from that in the IFG/IGT group (Fig. 1A).
First-phase insulin levels were signiﬁ-
cantly lower in the IFG (post hoc P 
0.02), IGT (P  0.009), and IFG/IGT
(P0.011)groupsandlowestinthetype
2 diabetic group (P  0.001) compared
with the NGT group (Fig. 1B). Similarly,
ﬁrst-phase C-peptide levels were lowest
in the type 2 diabetic group and signiﬁ-
cantly different between the type 2 dia-
betic and NGT groups (P  0.001).
Second-phase insulin (Fig. 1B) levels
were signiﬁcantly reduced in the type 2
diabetic group compared with the NGT
(P  0.001) and IGT (P  0.001) but not
the IFG (P  0.3) or IFG/IGT groups.
GDI, which represents insulin secretion
relative to insulin sensitivity, was signiﬁ-
cantly impaired in all categories of pre-
diabetes, was lowest in type 2 diabetes,
and was signiﬁcantly different from IFG
and IGT but not IFG/IGT (Fig. 1C). Youth
with type 2 diabetes receiving different
treatment modalities did not differ with re-
spect to their peripheral glucose disposal,
insulin secretion, or GDI (data not shown).
Determinants of fasting glucose and
oral glucose tolerance
Fasting glucose correlated with hepatic
insulin resistance (r  0.30, P  0.004),
Figure 1—A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT
(striped bar), IFG/IGT (diamond bars), and type 2 diabetes (T2DM) (ﬁlled bars). P values are for trend (ANOVA P values). B: First- and
second-phaseinsulinlevelsduringthehyperglycemicclampinNGT(E),IFG(   ),IGT( ),IFG/IGT(),andtype2diabetes(f).C:GDIinsubjects
withNGT(openbar),IFG(dottedbar),IGT(stripedbar),IFG/IGT(diamondbar),andtype2diabetes(ﬁlledbar).InAandC,lettersaresigniﬁcant
post hoc analysis (Bonferroni correction): P  0.05 (a, type 2 diabetes versus NGT; b, type 2 diabetes versus IFG; c, type 2 diabetes versus IGT; e,
NGT versus IFG/IGT; f, NGT versus IGT). Data are means  SD.
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and second-phase (r  0.47, P 
0.001)insulin,andwithGDI(r0.57,
P  0.001) but not with peripheral insu-
lin sensitivity. Similarly, 2-h OGTT glu-
cose correlated with ﬁrst-phase (r 
0.48, P  0.001) and second-phase
(r  0.40, P  0.001) insulin and with
GDI(r0.63,P0.001)butnotwith
insulin sensitivity. In a multiple regres-
sionanalysiswithage,sex,ethnicity,BMI,
hepatic insulin resistance, and GDI as in-
dependent variables and 2-h OGTT glu-
cose or fasting glucose as the dependent
variable, GDI was the signiﬁcant determi-
nant of the variance in the 2-h glucose
( 0.47, P  0.001) and the fasting
glucose ( 0.32, P  0.009). With
visceral adipose tissue or fat mass instead
of BMI in the regression model, GDI re-
mains the signiﬁcant determinant of the
variance in mean fasting glucose (
0.4,P0.001)andin2-hglucose(
0.5, P  0.001). The relationship be-
tweenGDIand2-hOGTTglucoseorfast-
ing glucose is depicted in Fig. 2.
CONCLUSIONS — In this study, we
hypothesized that for similar degrees of
adiposity insulin sensitivity will not differ
among the different pre-diabetic groups
compared with youth with NGT but will
be lower in youth with type 2 diabetes,
whereas insulin secretion will be im-
paired in all categories of glucose dys-
regulation. Consistent with our
hypothesis, the current ﬁndings demon-
strate that all pre-diabetes states in obese
youth of similar BMI, percent body fat,
and abdominal adiposity are character-
ized by reductions in -cell function rel-
ative to insulin sensitivity, with no
difference in insulin sensitivity. In youth
with IFG, insulin-stimulated glucose dis-
posal is preserved compared with that in
those with NGT, whereas ﬁrst- and sec-
ond-phase insulin secretion is 
50 and
30% impaired. In youth with IGT, ﬁrst-
phase insulin is 
40% lower compared
with that in those with NGT with preser-
vation of second-phase insulin. When
both defects, IFG and IGT, coexist, the
impairment in insulin secretion is a mix-
ture of both with 
55% lower ﬁrst-phase
insulin and 30% lower second-phase in-
sulin. In the full-blown diabetic state, in-
sulin-stimulated glucose disposal is
impaired by 
30%, ﬁrst-phase insulin is
impairedby
75%,andsecond-phasein-
sulin is impaired by 
65% compared
with those in youth with NGT. Such
cross-sectional observations are consis-
tent with longitudinal studies showing a
higherriskofprogressiontotype2diabe-
tes in the subjects with combined IFG/
IGT compared with those with isolated
IFG or IGT (15).
The present study conﬁrms the re-
sults in some of the existing adult liter-
ature but contradicts others. Our
ﬁndings are consistent with observa-
tions in adults demonstrating greater
impairment in insulin secretion in indi-
viduals with IFG (9,14,16,17) com-
pared with those with IGT, in that the
defect in insulin secretion involves both
ﬁrst-phase and second-phase insulin in
IFG, whereas second-phase insulin is
preserved in IGT. Moreover, adult stud-
ies indicate that the loss of -cell func-
tion may start at levels of FPG on the
higher end of the conventional normal
range (18). A recent longitudinal study
suggests that a defect in insulin secre-
tion (evaluated by an OGTT-derived in-
dex) is present in subjects with IFG and
apparent 5 years before the develop-
ment of fasting hyperglycemia (19). On
the other hand, other investigations in
adultsshowgreaterinsulinresistancein
IGT groups compared with IFG or NGT
groups unlike our ﬁndings (17,18).
However, a major difference between
our study and the adult studies, besides
the age factor, is that almost invariably,
the reported adults with IGT
(9,15,17,18,20) or IFG (9,15,18,20)
have higher BMI and/or abdominal fat
compared with the NGT groups, which
could contribute to the observed differ-
ences in insulin action between IGT,
IFG, and NGT categories. This observa-
tion is supported by the fact that when
subjects have similar anthropometric
measures (21), investigators did not
ﬁndsigniﬁcantdifferencesinperipheral
glucose uptake in the IFG or IFG/IGT
groups compared with the NGT group
(21). In addition, controlling for body
composition (BMI and waist-to-hip ra-
tio) eliminated differences in insulin
sensitivity among NGT, IFG, and IGT
subgroups in one study (22) and be-
tween IGT and NGT in another study
(23). In that same study, lower insulin
sensitivity is evident in the type 2 dia-
betic group compared with that in the
NGT group and with that in the pre-
diabetic groups after controlling for
overweight (23), consistent with our
current and previous ﬁndings (12).
In this study, use of the hyperglyce-
micclampallowedustoexaminesecond-
phase insulin secretion, information on
which is not widely available in the pub-
lished literature. The defect in ﬁrst-phase
insulin secretion in our pre-diabetic
groups is consistent with the ﬁndings of
Cali’ et al. (11) of decreased glucose sen-
sitivity of ﬁrst-phase insulin secretion in
the pre-diabetic state. In their study, ab-
solute values of ﬁrst- and second-phase
Figure2—RelationshipofGDItoFPG(A)and2-hOGTTglucoselevel(B)inNGT(E),IFG(   ),IGT( ),IFG/IGT(Œ),andtype2diabetes(f).
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ent in the pre-diabetic groups compared
withthoseintheNGTgroup,andglucose
sensitivity of second-phase insulin was
not affected except in the combined IFG/
IGT group. Their study, however, did not
include subjects with type 2 diabetes to
allow them to evaluate the magnitude of
impairment across the spectrum of glu-
cose tolerance. In our study, inclusion of
adolescents with type 2 diabetes allowed
us to assess not only deviations from nor-
mal but also differences from the extreme
abnormal. Although absolute levels of
second-phase insulin were signiﬁcantly
lower in the type 2 diabetic versus IGT
group, there was no difference between
the type 2 diabetic and IFG or coexisting
IFG/IGT groups. Such an observation
suggests that in IFG the impairment in
insulin secretion may play a more critical
role in the progression to type 2 diabetes
than is the case with IGT. Another con-
trast between the two studies is the study
population. Although our participants
were limited to a balanced representation
of African Americans and whites, their
study included subjects of multiple eth-
nicities with a signiﬁcant number of His-
panics who may differ in their metabolic
response to perturbations in glucose ho-
meostasis. In studies limited to Latino ad-
olescents, investigators did not ﬁnd
signiﬁcant differences in the acute insulin
response between those with IFG and
NGT (10) or between those with IGT and
NGT (24), although GDI was reduced in
the IFG and IGT groups compared with
that in the NGT group, indicating an im-
pairment in -cell function relative to in-
sulin sensitivity.
Several adult studies suggested that
the IFG state is characterized by hepatic
insulin resistance measured during the
euglycemic clamp (9,15,25). However,
the population in those studies consisted
of Mexican American adults in one (15)
and Native Americans (9) in another. In
addition, the pre-diabetic subjects had
higher BMI and waist circumference (15)
compared with those in the NGT group,
whichcouldhavecontributedtotheirhe-
patic insulin resistance. In a study by
Bock et al. (25), mild hepatic insulin re-
sistance was found in white subjects with
IFG compared with those with NGT,
which was attributed to increased glu-
coneogenesis. However, again the sub-
jects with IFG were signiﬁcantly more
obese and had higher visceral fat (25).
Ourstudyparticipantsintheﬁvedifferent
groups had comparable degrees of total
and abdominal adiposity, and thus it is
possible that with similar degrees of obe-
sity,theearliestdetectedabnormalityisin
-cell function and insulin secretion, and
hepatic insulin resistance develops later
and becomes more marked in individuals
of certain ethnic backgrounds. Therefore,
we propose that the defect in insulin se-
cretion in the IFG group in combination
with hepatic insulin resistance (which we
did not measure during the clamp) may
be responsible for the mild fasting hyper-
glycemia. On the other hand, the inter-
play between impaired insulin secretion
and peripheral insulin resistance in sub-
jects with coexisting IFG/IGT may pre-
vent maintenance of plasma glucose
withinanormalrangeafteraglucoseload.
One limitation in our study is the rel-
atively smaller sample size of the IFG and
combined IFG/IGT groups. However, the
use of the clamp, a sensitive method for
assessinginsulinsensitivityandsecretion,
allowed us to demonstrate signiﬁcant dif-
ferences in a ﬁve-group comparison.
In summary, all pre-diabetic states in
obese youth have impaired insulin secre-
tion relative to insulin sensitivity, al-
though the magnitude of impairment in
-cell function may be variable. Such dif-
ferencespotentiallytranslatetoadifferen-
tial in the risk of progression to type 2
diabetes. Further investigations into the
underlying mechanisms/reasons are
needed. The ultimate objective from such
scientiﬁc advances is to individualize the
therapeutic/preventive approach to the
speciﬁc underlying metabolic dysfunc-
tion, leading to type 2 diabetes at a young
age.
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